Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Globe Newswire•03/08/2026•08:00 ET
0
Whiz Insights
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes
Initiation marks advancement of Altimmune's lead program into late-stage development following positive IMPACT Phase 2b data
Get started
Create a free account to read the full story.